Fluticasone Furoate
FDA-approved product (spray, metered, nasal), marketed as Arnuity Ellipta, Flonase Sensimist Allergy Relief.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Airway obstruction
- Allergic rhinitis
- Asthma
- Chronic obstructive pulmonary disease
- Nasal congestion
- Rhinitis, Allergic, Perennial
- Seasonal allergic rhinitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids; Glucocorticoids
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA52.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae26.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Fluticasone Furoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Mefloquine HydrochlorideExisting use: Malaria, Plasmodium falciparum malaria, Plasmodium vivax malaria81.8% AI-predicted activityagainst M. tuberculosisLab records exist8 registered studies
- KetoconazoleExisting use: Adrenal gland disease, Blastomycosis, Cushing syndrome and 3 more81.2% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- LevoketoconazoleExisting use: Adrenal gland disease, Adrenal gland hyperfunction, Cushing syndrome81.2% AI-predicted activityagainst M. tuberculosis6 registered studies
- Fluphenazine DecanoateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosis4 registered studies
- Fluphenazine EnanthateExisting use: Mental or behavioural disorder, Psychosis80.7% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- NifurtimoxExisting use: American trypanosomiasis, Chagas disease, Leishmaniasis and 1 more78.4% AI-predicted activityagainst M. tuberculosis19 registered studies
- Fluphenazine HydrochlorideExisting use: Mental or behavioural disorder, Psychosis77.8% AI-predicted activityagainst M. tuberculosis5 registered studies
- NitazoxanideExisting use: Amebiasis, Diarrhea77.8% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TopiramateExisting use: Epilepsy, Lennox-Gastaut syndrome, Migraine disorder and 1 more77.4% AI-predicted activityagainst M. tuberculosisLab records exist50+ registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more76.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Chlorpromazine HydrochlorideExisting use: Conduct disorder, Mental or behavioural disorder, Nausea and vomiting and 3 more75.0% AI-predicted activityagainst M. tuberculosis33 registered studies
- ProchlorperazineExisting use: Anxiety disorder, Nausea and vomiting, Psychosis and 1 more74.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT00662805 · start 2004-06
Registered record
- Registry ID
- NCT00662805
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Salmeterol/Fluticasone propionate
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2004-06
- Completion
- 2008-09
- Enrolment
- 762
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Disease, Chronic ObstructiveInterventionSalmeterol/Fluticasone propionatePhaseNot recordedRegistry statusCompletedBone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
NCT00355342 · start 2004-04-28
Registered record
- Registry ID
- NCT00355342
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Salmeterol 50 mcg BID; Fluticasone Propionate/Salmeterol 250/50 mcg BID; DISKUS inhaler
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2004-04-28
- Completion
- 2007-09-06
- Enrolment
- 186
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Disease, Chronic ObstructiveInterventionSalmeterol 50 mcg BID; Fluticasone Propionate/Salmeterol 250/50 mcg BID; DISKUS inhalerPhasePhase 4Registry statusCompletedPilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00239499 · start 2003-09
Registered record
- Registry ID
- NCT00239499
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Tiotropium; Salmeterol plus Fluticasone
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2003-09
- Completion
- 2004-08
- Enrolment
- 107
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Disease, Chronic ObstructiveInterventionTiotropium; Salmeterol plus FluticasonePhasePhase 4Registry statusCompletedCOPD on Primary Care Treatment (COOPT)
NCT00184977 · start 1998-12
Registered record
- Registry ID
- NCT00184977
- Conditions
- Pulmonary Disease, Chronic Obstructive; Lung Diseases, Obstructive; Bronchitis, Chronic
- Interventions
- N-acetylcysteine; fluticasone propionate
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 1998-12
- Completion
- 2003-01
- Enrolment
- 270
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Disease, Chronic Obstructive; Lung Diseases, Obstructive; Bronchitis, ChronicInterventionN-acetylcysteine; fluticasone propionatePhasePhase 4Registry statusCompletedComparison of Two Treatment Regimens in Asthmatic Patients
NCT01488773 · start 1995-04
Registered record
- Registry ID
- NCT01488773
- Conditions
- Asthma
- Interventions
- first prescription of montelukast; first prescription of salmeterol
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 1995-04
- Completion
- 2006-06
- Enrolment
- 132
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAsthmaInterventionfirst prescription of montelukast; first prescription of salmeterolPhaseNot recordedRegistry statusCompleted